NanoPass Technologies News
14 articles
Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
NanoPass Technologies Secures Awz Ventures' $4M Investment, Signaling Growth and Innovation in Intradermal Delivery Technology
NanoPass Technologies, an innovator in intradermal delivery solutions, has secured a $4 million investment from Awz Ventures in a $6 million funding round. The funding will help NanoPass expand its commercial reach. The company has also appointed Daniel Levitats as its new CEO. NanoPass has developed the MicronJet platform, a next-generation technology for superior product delivery. The investment from Awz Ventures is part of its Active Capital strategy, providing NanoPass with multi-stage investment, mentorship, access to strategic partnerships, and preparation for future funding rounds and M&A opportunities.
InvestmentManagement Changes
ננופס תחל בניסוי במוצר שעשוי לשפר את יעילות חיסוני הקורונה
Israeli company Nanopass has received approval from the Israeli Ministry of Health to begin clinical trials for a coronavirus vaccine using a special subcutaneous injection technology. The product will be used in the clinical trial of the Biological Institutes vaccine, Brilife. The companys vaccination method reduces pain and also allows for an increase in the dosage of the vaccine reaching its target, effectively increasing the number of vaccine doses available to the state. The device developed by the company has already received FDA approval for subcutaneous injection and is also in trials for coronavirus in China. The technology can potentially be applied to other types of vaccines, including RNA vaccines.
InvestmentPartners
NanoPass's intradermal injection platform proven to sustain COVID-19 vaccine antibodies using 1/15 of the dose reports Chinese Institute of Medical Biology
A study conducted by IMB scientists and published by NanoPass has shown that intradermal COVID vaccination can effectively increase antibody levels. The study used NanoPasss MicronJet™600 device to administer a 1/15 dose of the vaccine intradermally, resulting in significant increases in antibody levels. The intradermal boost allowed for robust and sustained immunogenicity for at least six months. NanoPass CEO, Dr. Yotam Levin, commended the Chinese researchers for their work and highlighted the potential to multiply available vaccine doses by 15-fold. The study was a joint effort between NanoPass and YNC, with YNC supporting IMB. YNC CEO, Ni Jian, emphasized the importance of improving antibody levels and sustaining them for a longer time to combat COVID-19.
Partners
ננו-פאס פיתחה את המחט הרפואית הזעירה בעולם - Techtime - חדשות אלקטרוניקה והייטק
NanoPass, an Israeli medical device company, has signed a strategic agreement with Korean MEMS manufacturer Micro2Nano to develop a mass production infrastructure for the worlds smallest medical needles. The needles, less than a millimeter in length, are produced using MEMS technology and have been approved by the FDA. The partnership with Micro2Nano will allow NanoPass to manufacture millions of units per year. The tiny needles enable painless intradermal injections and have clinical advantages over subcutaneous or intramuscular injections. NanoPass aims to use the needles for vaccinations, aesthetic treatments, allergy testing, and other medical procedures. The company has conducted over 60 clinical trials with approximately 7,500 patients. The FDA-approved needle is made of silicone and has a three-dimensional hollow pyramid structure.
Partners
West Makes Investment in NanoPass Technologies
West Pharmaceutical Services, Inc. has announced a strategic investment in NanoPass Technologies Ltd. The investment will provide West with access to NanoPass knowledge and expertise in intradermal drug delivery and future collaboration opportunities. NanoPass will use the investment to advance its clinical development efforts and support the launch of its microneedle-based device for intradermal delivery of vaccines and drugs. West believes that intradermal drug delivery will be critical to the pharmaceutical and biotechnology industrys advancements in immunotherapy treatments. The partnership between West and NanoPass will enable the development of new vaccines and immunotherapies.
Investment
NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products
NanoPass Technologies has entered into a clinical supply and support agreement with Immune Design for the supply of its microneedle delivery device for use with Immune Designs oncology immunotherapy products. The agreement provides Immune Design with non-exclusive access and supply of the device for its cancer immunotherapy programs globally. This collaboration marks NanoPasss entry into the growing field of cancer immunotherapy. The financial terms of the agreement were not disclosed.
Partners
NanoPass Technologies Grants an Exclusive License to Circassia Pharmaceuticals, for use of its MicronJet600™ Device in Allergy Testing in the US
NanoPass Technologies has entered into a license agreement with Circassia Pharmaceuticals for the supply of its microneedle delivery device, MicronJet600, for allergy testing in the US market. This agreement expands the collaboration between the two companies, as Circassia is already using the device in its allergy immunotherapy clinical studies. The financial terms of the agreement were not disclosed. NanoPass aims to improve usability, accuracy, and patient satisfaction in allergy testing through the use of its reliable device. The company sees potential in expanding its collaborations beyond vaccines into fields such as allergy and cancer. NanoPass has conducted multiple clinical studies and is backed by prominent investors. Circassia is a specialty biopharmaceutical company focused on the development and commercialization of allergy immunotherapy products.
Partners
NanoPass Technologies Grants a Commercial License to Janssen Pharmaceuticals, Inc., for use of its MicronJet Device
NanoPass Technologies has entered into a license agreement with Janssen Pharmaceuticals for its microneedle delivery device, MicronJet. The agreement grants Janssen an exclusive license to use the device in its seasonal influenza programs and options for additional vaccine fields. The financial terms were not disclosed. NanoPass sees this agreement as a significant milestone towards full market acceptance and believes that combining its device approach with Crucells vaccines has the potential to improve immunogenicity and reduce the dose of vaccination. The MicronJet device has proven efficacy and safety in multiple applications, including flu vaccines and insulin.
Partners
Skin delivery solutions co NanoPass raises several million dollars
NanoPass Technologies has recently closed a new round of financing, led by Israel HealthCare Ventures. The amount raised was not disclosed but is believed to be several million dollars. The capital will be used to accelerate the market penetration of NanoPasss leading applications through additional licenses with pharmaceutical companies. As part of the financing, Dr. Hadar Ron of IHCV has joined NanoPasss board of directors. NanoPasss CEO, Dr. Yotam Levin, highlighted the companys technology for painless vaccine delivery and its ability to improve immune response with a reduced dose. IHCV managing partner, Dr. Ron, expressed the potential for the companys technology in other markets such as insulin delivery and aesthetics.
Investment
The Biologics News and Reports Portal
NanoPass Technologies has granted a license to its intradermal delivery device, MicronJet, to Circassia for use in multiple allergy vaccine fields. The license agreement will allow Circassia to use the device with its cat and ragweed allergy therapies, which will enter phase III clinical trials in 2012. The financial terms of the agreement were not disclosed. NanoPass Technologies sees this agreement as a significant fit between its device and Circassias patients needs. The company plans to make MicronJet a valuable component of its product offerings and has received positive feedback from patients and clinicians. NanoPass Technologies was founded by Dr. Shuki Yeshurun and is backed by prominent Israeli and US investors.
Partners
https://www.idri.org/idri-use-nanopass-micorneedle-technology/
Hate Needles? Now NanoPass needles offer painless vaccinations...
Israeli startup NanoPass Technologies has developed a nanotechnology product called the NanoPass needle, which aims to deliver pain-free injections by avoiding nerve endings. The needles tips are made of pure silicone crystals and measure less than one-micrometer in diameter. The company claims the technology is easier to administer and more comfortable for patients. The article discusses the potential impact of NanoPass needles on the vaccination process.
Customers
Intradermal drug delivery co NanoPass raises $6.5m
NanoPass Technologies Ltd. has closed its first financing round, raising $6.5 million from Ofer Hi Tech Ltd., WFD Ventures LLC, and D-Partners. The company will use the funds to complete clinical development and launch its product line. NanoPass has developed a platform for intradermal drug delivery using micro-pyramid devices. It was founded in 2000 and has raised a total of $1.6 million to date. The financing round marks a positive growth for the company.
Investment
